Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05026749 · ClinicalTrials.gov registry record · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
A Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
- 15
- Study locations
NCT05026749: Recruiting Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by University of Alabama at Birmingham.
NCT05026749 is a Phase 3 study of Respiratory Syncytial Virus Infections that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 370 participants, below the 1,074-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (66% lower). The trial reports 15 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05026749, a Phase 3 study of Respiratory Syncytial Virus Infections, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
- 15
- Study locations
Study Summary
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Primary Outcome
Duration of hospitalization in days for enrolled subjects
Conditions Studied
Interventions
- OTHER Control Group
- DRUG AZM Group
Study Locations (15)
Ohio
- Rainbow Babies and Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
Alabama
- The University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Children's National Hospital - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Children's Health - Indianapolis
Missouri
- St. Louis Children's Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2022-02-27 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 3 |
What NCT05026749 shows while recruiting
NCT05026749 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, below the 1,074-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT05026749 lists 15 locations in 14 states (Ohio, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT05026749 about?
NCT05026749 is a clinical study titled "Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children". The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
What is the current status of trial NCT05026749?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2022-02-27. Estimated completion is 2028-07-31.
What conditions does trial NCT05026749 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT05026749?
The interventions under investigation include: Control Group (OTHER), AZM Group (DRUG).
Who is sponsoring clinical trial NCT05026749?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05026749 being conducted?
This trial has 15 study locations across Alabama, California, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05026749's enrollment target sits among peer trials
370 10th of 21 higher than 12 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
COMPLETED · Phase 3
-
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- NCT05772845 · 370 participants · NA
Vaping and Smoking Withdrawal Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI